Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Klebsiella pneumoniae phage JD001
- Development stage
- Preclinical
- Lead developer
- Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Inhalation, Topical
01
Overview
JD001 is a lytic bacteriophage belonging to the genus *Jedunavirus* within the *Myoviridae* family, specifically characterized for its ability to infect and lyse *Klebsiella pneumoniae*. Discovered in seawater and genomicly sequenced, JD001 possesses a linear double-stranded DNA genome of approximately 48,408 to 49,482 base pairs. It is being researched as a potential antimicrobial agent for phage therapy, particularly against multidrug-resistant clinical strains of *K. pneumoniae*. The phage operates through a lytic cycle, where it attaches to the bacterial host, injects its genetic material, and hijacks the host's cellular machinery to produce new virions, ultimately resulting in the rupture of the bacterial cell wall and death of the pathogen.
- Other names
- JD001 phageJD-001 phageJD 001 phageKlebsiella phage JD001
02
Targets
Klebsiella pneumoniae cell-surface receptors
Beyond the preview
Go deeper on Klebsiella pneumoniae phage JD001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Klebsiella pneumoniae phage JD001.